Tag Archives: OTIC

Top Medical Stocks To Buy Right Now

Apollo Endosurgery (NASDAQ: APEN) and Arch Therapeutics (OTCMKTS:ARTH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.

Valuation & Earnings

Get Apollo Endosurgery alerts:

This table compares Apollo Endosurgery and Arch Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Apollo Endosurgery $64.31 million 1.73 -$27.29 million ($2.01) -3.16
Arch Therapeutics N/A N/A -$7.78 million N/A N/A

Arch Therapeutics has lower revenue, but higher earnings than Apollo Endosurgery.

Top Medical Stocks To Buy Right Now: Otonomy, Inc.(OTIC)

Advisors’ Opinion:

  • [By Logan Wallace]

    Otonomy Inc (NASDAQ:OTIC) has received a consensus rating of “Hold” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $9.58.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Otonomy (OTIC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Otonomy (OTIC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Alkermes (NASDAQ: ALKS) and Otonomy (NASDAQ:OTIC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings.

  • [By Max Byerly]

    Otonomy (NASDAQ:OTIC) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.06), Fidelity Earnings reports. The company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.30 million. Otonomy had a negative net margin of 6,316.88% and a negative return on equity of 58.60%.

Top Medical Stocks To Buy Right Now: L-3 Communications Holdings, Inc.(LLL)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on L3 Technologies (LLL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Shares of L3 Technologies (NYSE:LLL) have received a consensus recommendation of “Buy” from the fourteen analysts that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $223.00.

  • [By Lou Whiteman]

    L-3 Technologies (NYSE:LLL) missed out on much of the rally enjoyed by other defense contractors over the last year. The reason for the lagging performance was because the company was in the middle of a transformation plan aimed at propelling it into the ranks of those larger rivals. Judging by its first-quarter results, the efforts are already beginning to show results.

  • [By Joseph Griffin]

    Sei Investments Co. lifted its stake in L3 Technologies Inc (NYSE:LLL) by 31.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,947 shares of the aerospace company’s stock after buying an additional 7,970 shares during the period. Sei Investments Co.’s holdings in L3 Technologies were worth $6,336,000 at the end of the most recent reporting period.

  • [By Logan Wallace]

    NEXT Financial Group Inc purchased a new position in shares of L3 Technologies Inc (NYSE:LLL) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 978 shares of the aerospace company’s stock, valued at approximately $203,000.

  • [By Joseph Griffin]

    Colony Group LLC lifted its holdings in shares of L3 Technologies Inc (NYSE:LLL) by 1.6% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 22,697 shares of the aerospace company’s stock after purchasing an additional 363 shares during the quarter. Colony Group LLC’s holdings in L3 Technologies were worth $4,365,000 as of its most recent filing with the Securities and Exchange Commission.

Top Medical Stocks To Buy Right Now: CHS Inc(CHSCO)

Advisors’ Opinion:

  • [By Shane Hupp]

    Media headlines about CHS Inc Preferred Shares Class B (NASDAQ:CHSCO) have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. CHS Inc Preferred Shares Class B earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.8637910025833 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Top Medical Stocks To Buy Right Now: S&W Seed Company(SANW)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on S&W Seed (SANW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Get a free copy of the Zacks research report on S&W Seed (SANW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Alico (NASDAQ: ALCO) and S&W Seed (NASDAQ:SANW) are both small-cap consumer staples companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.

  • [By Ethan Ryder]

    S&w Seed (NASDAQ:SANW) – Equities researchers at B. Riley decreased their Q3 2019 earnings per share (EPS) estimates for S&w Seed in a research note issued to investors on Thursday, May 10th. B. Riley analyst S. Sherbetchyan now anticipates that the company will post earnings of $0.00 per share for the quarter, down from their previous forecast of $0.01. B. Riley has a “Buy” rating and a $5.50 price objective on the stock.

Top Medical Stocks To Buy Right Now: Blueprint Medicines Corporation(BPMC)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Fernwood Investment Management LLC lessened its holdings in shares of Blueprint Medicines (NASDAQ:BPMC) by 29.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,696 shares of the biotechnology company’s stock after selling 1,120 shares during the period. Fernwood Investment Management LLC’s holdings in Blueprint Medicines were worth $247,000 at the end of the most recent reporting period.

  • [By Ethan Ryder]

    Mutual of America Capital Management LLC acquired a new position in shares of Blueprint Medicines Corp (NASDAQ:BPMC) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 10,500 shares of the biotechnology company’s stock, valued at approximately $667,000.

  • [By ]

    Blueprint Medicines (Nasdaq: BPMC), similarly to Loxo, is working on cancer medications that can target different mutations, and target them with precision. No wonder the stock rallied more than 14% this year, and that’s on top of the share-price more than doubling in the last three years. By 2020, BPMC plans to have two products already on the market, with four more pending. This company could certainly become a target for a larger peer, especially if its 2020 plan remains on track.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Blueprint Medicines (BPMC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Todd Campbell]

    The big thing to watch this week will be how investors view Loxo’s results in comparison to results presented earlier this year by Blueprint Medicines (NASDAQ:BPMC). Blueprint’s BLU-667 also targets RET-fusions and at the American Association for Cancer Research meeting in April, Blueprint revealed a preliminary overall response rate of 50% for NSCLC and 40% for MTC. It’s bad science to compare unrelated trials, so investors might be best off viewing Loxo and Blueprint’s data as evidence that they’re both working on a winning approach.

Top Medical Stocks To Buy Right Now: Costamare Inc.(CMRE)

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on COSTAMARE Inc/SH (CMRE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    COSTAMARE Inc/SH (NYSE:CMRE) has received an average recommendation of “Hold” from the seven analysts that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $7.75.

  • [By Rich Smith]

    Shares of three big oceangoing container-shipping companies — Triton International (NYSE:TRTN), Seaspan (NYSE:SSW), and Costamare (NYSE:CMRE) — suffered huge losses in early trading Friday after Wells Fargo announced it was downgrading “the entire container complex,” as StreetInsider.com put it.

  • [By Logan Wallace]

    COSTAMARE Inc/SH (NYSE:CMRE) shares hit a new 52-week high during trading on Tuesday following a dividend announcement from the company. The stock traded as high as $8.15 and last traded at $8.10, with a volume of 15988 shares trading hands. The stock had previously closed at $7.98.

Best Small Cap Stocks To Invest In 2019

Small cap hair loss stocks Aclaris Therapeutics (NASDAQ: ACRS), Cytori Therapeutics (NASDAQ: CYTX) and RepliCel Life Sciences (OTCQB: REPCF; CVE: RP) are trying to tap into a big market as currently, there are only two FDA-approved drugs available for the treatment of Androgenetic Alopecia (AGA) – also known as male or female pattern baldness (one of which cannot be used by women). Thus, a significant unmet need exists for a safe and efficacious product – especially since its experienced by 70% of men and 40% of women as they age.

Right now, hair loss sufferers generally try Minoxidil (aka Rogaine), which was developed in the late 1950s by the Upjohn Company (later became part of Pfizer); or Propecia, which is manufactured by the pharmaceutical giant Merck & Co (NYSE: MRK). However, there are other treatments in the pipeline being advanced by big and small cap pharma or biotech stocks. For example: In 2015, large cap Allergan plc (NYSE: AGN) acquired small cap Kythera Biopharmaceuticals for $2.1 billion to add treatments for double chins and male pattern baldness. By acquiring Kythera, Allergan gained a one-two punch for treating hair loss as it also has Bimatoprost (originally an eye treatment) in the pipeline as a topical hair growth treatment after it was found to lengthen and thicken women’s eyelashes.

Best Small Cap Stocks To Invest In 2019: iShares Mortgage Real Estate Capped (REM)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Remme (CURRENCY:REM) traded 1.4% higher against the U.S. dollar during the twenty-four hour period ending at 22:00 PM E.T. on August 31st. Remme has a market cap of $4.00 million and $344,172.00 worth of Remme was traded on exchanges in the last 24 hours. One Remme token can now be bought for $0.0066 or 0.00000094 BTC on major exchanges including Tidex, Kuna, DEx.top and Gate.io. During the last seven days, Remme has traded up 7.7% against the U.S. dollar.

  • [By Stephan Byrd]

    Remme (REM) is a token. It launched on December 4th, 2017. Remme’s total supply is 1,000,000,000 tokens and its circulating supply is 614,315,410 tokens. Remme’s official Twitter account is @remme_io and its Facebook page is accessible here. The Reddit community for Remme is /r/remme and the currency’s Github account can be viewed here. The official website for Remme is remme.io. The official message board for Remme is medium.com/remme.

  • [By Shane Hupp]

    Stifel Financial Corp decreased its stake in iShares FTSE NAREIT Mortg.REITIn Fd (BMV:REM) by 57.3% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,921 shares of the company’s stock after selling 13,308 shares during the quarter. Stifel Financial Corp’s holdings in iShares FTSE NAREIT Mortg.REITIn Fd were worth $422,000 at the end of the most recent quarter.

  • [By Stephan Byrd]

    Remme (CURRENCY:REM) traded up 1.2% against the US dollar during the 24-hour period ending at 14:00 PM E.T. on August 19th. Remme has a total market capitalization of $4.41 million and approximately $486,178.00 worth of Remme was traded on exchanges in the last day. One Remme token can now be bought for $0.0073 or 0.00000115 BTC on major cryptocurrency exchanges including Tidex, IDEX, DEx.top and Kuna. Over the last week, Remme has traded 15.2% lower against the US dollar.

Best Small Cap Stocks To Invest In 2019: Urban Outfitters Inc.(URBN)

Advisors’ Opinion:

  • [By Garrett Baldwin]

    Click here now.

    Stocks to Watch Today: TGT, CRM, FB
    This morning, shares of Target Corp. (NYSE: TGT) popped nearly 6% after a strong Q4 earnings report. The company reported earnings per share of $1.53 on total revenue of $22.98 billion. Wall Street expected $1.52 per share on sales of $22.91 billion. The firm reported very strong online sales (up 25%) and a 5.3% jump in same-store sales. Analysts had expected a 4.5% increase in same-store sales. The report is the latest sign that Target has emerged as a formidable competitor to Amazon.com Inc. (NASDAQ: AMZN) and Walmart Inc. (NYSE: WMT). Facebook Inc. (NASDAQ: FB) is under fire again due to security concerns around its sign-in features. The company has not allowed users to opt out of the key feature that lets users look up others by phone number and e-mail address. Many people have added their phone numbers in the past thinking it would only be used for two-factor authentication and security. Critics argue this is the latest episode of Facebook compromising user information. Shares of Salesforce.com Inc. (NYSE: CRM) are in focus as the cloud computing giant plans to report earnings after the bell Tuesday. CRM stock is already up 20% so far this year. And many analysts expect the firm to report earnings per share of $0.55 on top of $3.56 billion in revenue. Yesterday, Salesforce co-CEO Marc Benioff predicted that $30 billion in annual revenue for the cloud computing giant is “right around the corner.” Look for earnings reports from AeroVironment Inc. (NASDAQ: AVAV), Ambarella Inc. (NASDAQ: AMBA), Ciena Corp. (NASDAQ: CIEN), Kohl’s Corp. (NYSE: KSS), Ross Stores Inc. (NASDAQ: ROST), Sina Corp. (NASDAQ: SINA), Urban Outfitters Inc. (NASDAQ: URBN), Vivint Solar Inc. (NASDAQ: VSLR), and Weibo Corp. (NYSE: WB).

    Follow Money Morning on Facebook, Twitter, and LinkedIn.

  • [By Chris Lange]

    Urban Outfitters Inc. (NASDAQ: URBN) released its most recent quarterly results after the markets closed on Tuesday. The firm ultimately came out on top of this most recent report, keeping its strong winning streak alive, and thanks to the help of analysts rushing to its side.

  • [By ]

    Afterwards, I couldn’t stop thinking about Urban Outfitters (Nasdaq: URBN). This trendy clothing, furniture, decor and (now) makeup store — born in the city of brotherly love — is set for another breakout as it continues to fire on all cylinders.

  • [By Motley Fool Transcription]

    Urban Outfitters, Inc. (NASDAQ:URBN) Q2 2019 Earnings Conference Call Aug. 21, 2018, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Best Small Cap Stocks To Invest In 2019: Otonomy, Inc.(OTIC)

Advisors’ Opinion:

  • [By Max Byerly]

    Otonomy (NASDAQ:OTIC) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.06), Fidelity Earnings reports. The company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.30 million. Otonomy had a negative net margin of 6,316.88% and a negative return on equity of 58.60%.

  • [By Logan Wallace]

    Alkermes (NASDAQ: ALKS) and Otonomy (NASDAQ:OTIC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Otonomy (OTIC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Otonomy Inc (NASDAQ:OTIC) has received a consensus rating of “Hold” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $9.58.